Cara McAnaney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cara McAnaney has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
April Nakayoshi
Department of Family and Community Medicine, University of California , San Francisco, United States
1 shared publication- Carolyn Chu
Department of Family and Community Medicine, University of California , San Francisco, United States
1 shared publication - Chris Bositis
Department of Family and Community Medicine, University of California , San Francisco, United States
1 shared publication - Monica Gandhi
Division of HIV, Infectious Disease, and Global Medicine, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA
1 shared publication - Parya Saberi
Division of Prevention Science University of California San Francisco San Francisco California USA
1 shared publication
Latest Publications
- Open Access
- 17 October 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Lenacapavir Plus Cabotegravir as Combination Treatment: Real-world Use Cases From the National Clinician Consultation Center
Background: The use of long-acting injectable (LAI) lenacapavir (LEN) plus cabotegravir (CAB) +/− rilpivirine (RPV) may increase viral suppression in people with HIV (PWH) with a history of oral antiretroviral therapy (ART) adherence challenges or drug-resistant virus. Data on the LEN+ CAB+/−RPV effectiveness and tolerability are limited. Methods: We report observations on real-world LEN+ CAB+/−RPV use from the National Clinician Consultation Center (NCCC), a federally funded teleconsultation resource for US-based clinicians. Providers contacting NCCC from 1 December 2022 to 30 August 2024 for cases related to ART modification to LEN+ CAB+/−RPV were surveyed. Data from NCCC's secure database and survey responses were summarized using descriptive statistics. Results: Among 76 potential cases, 50 (66%) surveys were completed. Of these, 14 (28%) modified ART to LEN+ CAB+/−RPV, including 9 (64%) who changed to LEN+ CAB/RPV and 1 (7%) to LEN+ CAB, and 4 (29%) with no regimen details. ART modification was not made in 35 cases, and in one, the provider was unsure of changes. Nonexclusive reasons for LAI-ART modifications included viremia on oral ART (n = 6, 43%), inability/refusal to take oral ART (3, 21%), non-nucleoside reverse transcriptase inhibitor mutation(s) (3, 21%), integrase strand transferase inhibitor mutation(s) (2, 14%), or persistent viremia on CAB/RPV alone (2, 14%). LEN+ CAB+/−RPV was effective and well-tolerated: among 10 cases with follow-up information, viral load decreased by a mean of 3.88log10 copies/mL within a median of 56 days (range = 29–166 days), and 5 experienced injection-site reactions rated as “not at all” to “slightly” problematic. Conclusions: These data support further investigations into LEN+ CAB+/−RPV use among PWH with oral ART challenges and/or drug resistance.
- 17 October 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Open AccessLenacapavir Plus Cabotegravir as Combination Treatment: Real-world Use Cases From the National Clinician Consultation Center
Background: The use of long-acting injectable (LAI) lenacapavir (LEN) plus cabotegravir (CAB) +/− rilpivirine (RPV) may increase viral suppression in people with HIV (PWH) with a history of oral antiretroviral therapy (ART) adherence challenges or drug-resistant virus. Data on the LEN+ CAB+/−RPV effectiveness and tolerability are limited. Methods: We report observations on real-world LEN+ CAB+/−RPV use from the National Clinician Consultation Center (NCCC), a federally funded teleconsultation resource for US-based clinicians. Providers contacting NCCC from 1 December 2022 to 30 August 2024 for cases related to ART modification to LEN+ CAB+/−RPV were surveyed. Data from NCCC's secure database and survey responses were summarized using descriptive statistics. Results: Among 76 potential cases, 50 (66%) surveys were completed. Of these, 14 (28%) modified ART to LEN+ CAB+/−RPV, including 9 (64%) who changed to LEN+ CAB/RPV and 1 (7%) to LEN+ CAB, and 4 (29%) with no regimen details. ART modification was not made in 35 cases, and in one, the provider was unsure of changes. Nonexclusive reasons for LAI-ART modifications included viremia on oral ART (n = 6, 43%), inability/refusal to take oral ART (3, 21%), non-nucleoside reverse transcriptase inhibitor mutation(s) (3, 21%), integrase strand transferase inhibitor mutation(s) (2, 14%), or persistent viremia on CAB/RPV alone (2, 14%). LEN+ CAB+/−RPV was effective and well-tolerated: among 10 cases with follow-up information, viral load decreased by a mean of 3.88log10 copies/mL within a median of 56 days (range = 29–166 days), and 5 experienced injection-site reactions rated as “not at all” to “slightly” problematic. Conclusions: These data support further investigations into LEN+ CAB+/−RPV use among PWH with oral ART challenges and/or drug resistance.